23 Feb AlloVir
Diana Brainard, M.D., CEO
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single-, and multi-virus-specific T cell therapies targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viral diseases within a single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its robust product portfolio.